VEA
LRMR icon

Virtus ETF Advisers’s Larimar Therapeutics LRMR Stock Holding History

Virtus ETF Advisers’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,635
Closed -$45K – 632
2024
Q4 		$45K Buy
11,635
+2,127
+22% +$14K 0.02% 461
2024
Q3 		$62.3K Buy
9,508
+166
+2% +$1.33K 0.03% 437
2024
Q2 		$67.7K Buy
+9,342
New +$71.5K 0.03% 437

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Virtus ETF Advisers's LRMR Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Larimar Therapeutics (LRMR) in Q1 2025, closing a stake of 11,635 shares — an estimated $45K sold.

Virtus ETF Advisers first reported a position in LRMR in Q2 2024 and held it in 3 quarters. The position peaked at $67.7K in Q2 2024. 103 funds tracked by Wall St. Rank hold LRMR as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Larimar Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 11,635 Larimar Therapeutics shares in Q1 2025, an estimated $45K.
  • Virtus ETF Advisers first reported a position in Larimar Therapeutics in Q2 2024 and held it in 3 quarters.
  • Virtus ETF Advisers's Larimar Therapeutics position peaked at $67.7K in Q2 2024.
  • 103 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.